Critical Advances in Systemic Therapy for HCC: Building on Recent Progress for Community Practices

Download All
Explore recent data surrounding contemporary HCC treatment with this program featuring expert commentaries, an on-demand Webcast, and downloadable slides.
Mark Yarchoan, MD
Program Director
Richard S. Finn, MD


Atezolizumab plus bevacizumab was recently approved as first-line systemic therapy for patients with advanced HCC. Read an expert’s thoughts how this new approach will fit into contemporary treatment paradigms.

Richard S. Finn, MD Released: September 15, 2020

When should patients with HCC be transitioned from locoregional to systemic therapy to maximize therapeutic benefit? In this commentary, HCC expert Richard Finn, MD, provides his thoughts on this important question.

Richard S. Finn, MD Released: October 20, 2020

Review expert insights into the selection of optimal systemic treatment for patients with advanced HCC and Child-Pugh B liver disease.

Mark Yarchoan, MD
Program Director
Released: November 18, 2020
Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis, Inc.
Genentech, a member of the Roche Group
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings